The Japanese Journal of Urology
Online ISSN : 1884-7110
Print ISSN : 0021-5287
ISSN-L : 0021-5287
ASSAY OF URINARY PYRIDINOLINE AND DEOXYPYRIDINOLINE AS POTENTIAL MARKERS OF THE RATE OF BONE RESORPTION
Usefulness of Urinary Pyridinoline and Deoxypyridinoline in Patients with Prostate Cancer with Bone Metastases
Shin-ichi TakeuchiKen-ichiro Yoshida
Author information
JOURNALS FREE ACCESS

1994 Volume 85 Issue 10 Pages 1521-1527

Details
Abstract

The collagen crosslinks, pyridinoline (Pyr) and deoxypyridinoline (D-Pyr), were recently identified as potential markers of the rate of bone resorption. To determine whether urinary concentrations of Pyr and D-Pyr might provide an early warning of bone metastases in patients being monitored for cancer of the prostate, we compared these two newer parameters with the conventional indicators, that is, the serum concentrations of Bone Gla protein (BGP: osteocalcin) and alkaline phosphatase (ALP), in patients with prostate cancer with and without bone metastases vs. those of age-matched patients with benign prostatic hyperplasia (BPH). Urinary excretion of these compounds, expressed as a ratio to urinary creatinine (mg/dl), was determined by high performance liquid chromatography (HPLC) in 23 patients with prostate cancer (16 with bone metastases and 7 without bone metastases) and in 23 patients with BPH. The mean values of urinary Pyr and D-Pyr; 65.02±38.16pmol/μmol of creatinine and 8.87±7.01pmol/μmol of creatinine and 8.87±7.01pmol/μmol of creatinine, respectively, for patients with bone metastases of prostate cancer were significantly higher than those for patients without bone metastases of prostate cancer (27.43±10.29pmol/μmol of creatinine and 4.24±1.88pmol/μmol of creatinine) or for patients with BPH (25.58±7.54pmol/μmol of creatinine and 3.52±1.07pmol/μmol of creatinine). Among these three groups of patients, there were statistically significant (Pyr: P=0.0001, D-Pyr: P=0.001). The mean value of serum ALP for patients with bone metastases of prostate cancer (266.50±147.46IU/L) was significantly higher than that for patients without bone metastases of prostate cancer (135.14±20.32IU/L) and for patients with BPH (144.52±30.95IU/L) (P=0.0001). Urinary levels of both Pyr and D-Pyr were significantly correlated with serum ALP activity in patients with prostate cancer with bone metastases. Contrary to above results, differences in serum BGP levels of three groups of patients were not statistically significant.
Measurement of urinary Pyr and D-Pyr may provide a useful marker of metastatic spread to bone in patients with prostate cancer.

Information related to the author
© Japanese Urological Association
Previous article Next article
feedback
Top